|Day Low/High||234.86 / 238.35|
|52 Wk Low/High||184.50 / 281.28|
Get your plan in place, but understand that the Republic is not in jeopardy.
First and Only Hyaluronic Acid (HA) Dermal Filler FDA Approved for the Correction of Moderate to Severe Wrinkles and Folds, such as Nasolabial Folds, That Lasts up to 18 Months(1,2*)
Fed's rate hike gives markets a midweek boost. In the portfolio, we trim 1 position and add to 3 others.
Jim Cramer says economic fundamentals remain strong and this market's rallying with relief at Fed's anticipated rate hike.
The deal announced Tuesday gives Allergan exclusive access to five Editas programs aimed at serious, inherited eye diseases.
Editas Medicine, Amphastar Pharmaceuticals, Aratana Therapeutics and Pacira Pharmaceuticals were among the biotech stock movers in premarket trading on Tuesday.
47% OF RESPONDENTS SAID THEY ARE BOTHERED BY THE APPEARANCE OF THE AREA UNDER THEIR CHIN(1)
Common Encourages Americans to Take Action When it Comes to Their Vision Care and Visit their Eye Doctor
Doug Kass shares his thoughts on Allergan, and says that Caterpillar remains purr-fect for shorting.
Doug Kass shares his thoughts on the state of the market, and notices that the irrational might now be rationalized.
After the jobs report, the markets look ahead to the Fed. In the portfolio, we exit a position while adding to 4 others.
Why the name is sagging, and what it will take to spur the sector higher.
To put it simply, Stanley Black & Decker and Thermo Fisher screwed up.
A firestorm in Washington has created a fire sale for shares of this undervalued stock.
- Application Seeks to Expand VRAYLAR Label to Include Phase 3 Clinical Data for the Maintenance Treatment of Schizophrenia-
Logitech CEO Bracken Darrell tells Jim Cramer that the cloud is the new growth platform for Logitech.
Jim Cramer is bullish on Arconic, Treehouse Foods, Magellan Midstream Partners.
Jim Cramer says if Trump really wants to lower drug prices, he should target our trading partners.
Tesla's slide doesn't spell doom for other carmakers and it might be a buying opportunity for some investors, says Jim Cramer.
We would not be surprised to see investors continue to act cautiously as we wait for upcoming macro data and monetary policy decisions to hit the tape.
Investors are deciding what to make of an impending overhaul of the American health care system in the wake of legislative progress out of Washington.
Markets retreat late in the week while focusing on the Fed and the Trump administration. We add a tech name to the portfolio.
Growth is not only about the occupant of the Oval Office, say Jim Cramer. This is a genuine bull market, and it's about how you invest.